✦ LIBER ✦

Efficacy and Safety of Antioxidant Treatment With -Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 trial

✍ Scribed by Ziegler, D.; Low, P. A.; Litchy, W. J.; Boulton, A. J. M.; Vinik, A. I.; Freeman, R.; Samigullin, R.; Tritschler, H.; Munzel, U.; Maus, J.

Book ID: 111863335
Publisher: American Diabetes Association
Year: 2011
Tongue: English
Weight: 798 KB
Volume: 34
Category: Article
ISSN: 0149-5992
DOI: 10.2337/dc11-0503

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of diabetic polyneuropathy wit

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid ( α -lipoic acid): A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II)

✍ Reljanovic, M.; Reichel, G.; Rett, K.; Lobisch, M.; Schuette, K.; Möller, W.; Tr 📂 Article 📅 1999 🏛 Informa plc 🌐 English ⚖ 732 KB

Treatment of symptomatic diabetic polyne

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy

✍ Ziegler, D.; Hanefeld, M.; Ruhnau, K. J.; Hasche, H.; Lobisch, M.; Schutte, K.; 📂 Article 📅 1999 🏛 American Diabetes Association 🌐 English ⚖ 610 KB

Safety and efficacy of 4% hydroquinone c

Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma

✍ Ian L. Guevara; Amit G. Pandya 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

The efficacy and safety of the dipeptidy

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

✍ Robert Frederich, Robert McNeill, Niklas Berglind, Douglas Fleming, Roland Chen 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 239 KB

Evidence for safety and efficacy of rise

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study

✍ Steven Boonen; Roman S. Lorenc; Dietrich Wenderoth; Karen J. Stoner; Rachelle Eu 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 235 KB

Efficacy and safety of the glucagon-like

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

✍ Van Gaal, Luc; Souhami, Elisabeth; Zhou, Tianyue; Aronson, Ronnie 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 657 KB